Sunday, November 8, 2020
- 9:00AM-11:00AM
-
Abstract Number: 1233
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs- 9:00AM-11:00AM
-
Abstract Number: 1166
Use of Rituximab to Treat COPA Syndrome: A Multi-Institutional Cohort
Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma- 9:00AM-11:00AM
-
Abstract Number: 1175
Using a Patient-Engaged Approach to Identify Cross-Cutting Disease Factors Impacting Mental Health in Youth with Rheumatologic Disease
Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma- 9:00AM-11:00AM
-
Abstract Number: 1276
Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1208
Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial
RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs- 9:00AM-11:00AM
-
Abstract Number: 1304
Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Prospective French Nationwide Cohort
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1165
Validation of Healthcare Claims Algorithms for Identification of Herpes Zoster Among Children with Autoimmune/Autoinflammatory Disease
Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma- 9:00AM-11:00AM
-
Abstract Number: 1348
What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III- 9:00AM-11:00AM
-
Abstract Number: 1212
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)
RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs- 10:00AM-10:50AM
-
Abstract Number: 1460
“Can I Help You with Your RA Today?”: A Pilot Study on the User Experience with a Voice-Enabled Smartphone App to Virtually Monitor Disease Activity and Collect ePROs in Rheumatoid Arthritis
Clinical Practice II (1457–1461)- 10:00AM-10:50AM
-
Abstract Number: 1453
A First in Class Therapeutic Nanoparticle for Specific Targeting of Anti-citrullinated Protein Antibody Ameliorates Serum Transfer and Collagen Induced Arthritis
B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1452–1456)- 10:00AM-10:50AM
-
Abstract Number: 1478
A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center
Miscellaneous Rheumatic & Inflammatory Diseases II: Evaluating Drug Therapies for COVID-19 (1477–1481)- 10:00AM-10:50AM
-
Abstract Number: 1481
A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations
Miscellaneous Rheumatic & Inflammatory Diseases II: Evaluating Drug Therapies for COVID-19 (1477–1481)- 10:00AM-10:50AM
-
Abstract Number: 1480
Abatacept for the Treatment of IgG4-Related Disease